Early Metabolic Response by PET Predicts Sensitivity to Next-Line Targeted Therapy in EGFR -Mutated Lung Cancer with Unknown Mechanism of Acquired Resistance
Journal of Nuclear Medicine · 2024-06 · 65 (6) · 851-855
DOI: 10.2967/jnumed.123.266979 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 04.04.2024. Verfasst von Martin Schuler und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany; martin.schuler@uk-essen.de. Hauptthemen laut MEDLINE: Lung Neoplasms, ErbB Receptors, Drug Resistance, Neoplasm, Mutation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
Targeted therapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has established the precision oncology paradigm in lung cancer. Most patients with EGFR-mutated lung cancer respond but eventually acquire resistance.
Methods
Patients exhibiting the EGFR p.T790M resistance biomarker benefit from sequenced targeted therapy with osimertinib. We hypothesized that metabolic response as detected by 18F-FDG PET after short-course osimertinib identifies additional patients susceptible to sequenced therapy.
Results
Fourteen patients with EGFR-mutated lung cancer and resistance to first- or second-generation EGFR TKI testing negatively for EGFR p.T790M were enrolled in a phase II study. Five patients (36%) achieved a metabolic 18F-FDG PET response and continued osimertinib. In those, the median duration of treatment was not reached (95% CI, 24 mo to not estimable), median progression-free survival was 18.7 mo (95% CI, 14.6 mo to not estimable), and median overall survival was 41.5 mo.
Conclusion
Connecting theranostic osimertinib treatment with early metabolic response assessment by PET enables early identification of patients with unknown mechanisms of TKI resistance who derive dramatic clinical benefit from sequenced osimertinib. This defines a novel paradigm for personalization of targeted therapies in patients with lung cancer dependent on a tractable driver oncogene.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany; martin.schuler@uk-essen.de.
- Medical Faculty, University Duisburg-Essen, Essen, Germany.
- National Center for Tumor Diseases West, Essen, Germany.
- Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.
- Department of Pulmonary Medicine, West German Cancer Center, University Medicine Essen-Ruhrlandklinik, Essen, Germany.
- Department of Medicine I, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany.
Zitieren
APA
Schuler, M., Hense, J., Darwiche, K., Michels, S., Hautzel, H., Kobe, C., Lueong, S., Metzenmacher, M., Herold, T., Zaun, G., Laue, K., Drzezga, A., Theegarten, D., Nensa, F., Wolf, J., Herrmann, K., & Wiesweg, M. (2024). Early Metabolic Response by PET Predicts Sensitivity to Next-Line Targeted Therapy in EGFR -Mutated Lung Cancer with Unknown Mechanism of Acquired Resistance. Journal of Nuclear Medicine, 65(6), 851-855. https://doi.org/10.2967/jnumed.123.266979
Vancouver
Schuler M, Hense J, Darwiche K, Michels S, Hautzel H, Kobe C, et al. Early Metabolic Response by PET Predicts Sensitivity to Next-Line Targeted Therapy in EGFR -Mutated Lung Cancer with Unknown Mechanism of Acquired Resistance. Journal of Nuclear Medicine. 2024;65(6):851-855. doi:10.2967/jnumed.123.266979
BibTeX
@article{Schuler2024,
author = {Schuler, Martin and Hense, Jörg and Darwiche, Kaid and Michels, Sebastian and Hautzel, Hubertus and Kobe, Carsten and Lueong, Smiths and Metzenmacher, Martin and Herold, Thomas and Zaun, Gregor and Laue, Katharina and Drzezga, Alexander and Theegarten, Dirk and Nensa, Felix and Wolf, Jürgen and Herrmann, Ken and Wiesweg, Marcel},
title = {Early Metabolic Response by PET Predicts Sensitivity to Next-Line Targeted Therapy in EGFR -Mutated Lung Cancer with Unknown Mechanism of Acquired Resistance},
journal = {Journal of Nuclear Medicine},
year = {2024},
volume = {65},
number = {6},
pages = {851--855},
doi = {10.2967/jnumed.123.266979}
}
EUVIMED